Skip to main content

Advertisement

SpringerLink
Log in

Subretinal injection of ranibizumab in advanced pediatric vasoproliferative disorders with total retinal detachments

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To describe the surgical procedures, outcomes, and complications of a novel technique of subretinal injection of ranibizumab (SRR).

Methods

Between September 2012 and September 2018, 37 eyes of 26 consecutive children with vascularly active total retinal detachments in 1 or both eyes treated with SRR as primary treatment were included in this retrospective study. All included eyes received subretinal injection of ranibizumab (0.25 mg/ 0.025 ml). Data included demographics, ocular examination, and anatomic outcomes, following treatment and complications of eyes after SRR were collected.

Results

Eleven patients had bilateral SRR injections and 15 had monocular SRR injection. Thirteen patients were diagnosed as retinopathy of prematurity. Of all patients, the mean gestational age was 34.5 ± 5.1 weeks (range: 29.6~40.7 weeks), and birth weight was 2328.1 ± 1083.9 g (range: 940~3900 g). On 1-week postoperative follow-up, vascular activity decreased in all 37 eyes (100%). On the 1-month postoperative follow-up, vascular activity decreased but remained in 24 eyes (24/35, 68.6%) of 16 patients and vanished in 11 eyes (11/35, 31.4%) of 9 patients. No eye needed a secondary anti-VEGF therapy. Local subconjunctival hemorrhage was noted in two eyes (2/37, 5.4%). Localized wound leakage of subretinal fluid was also noted in one eye (1/37, 2.7%).

Conclusions

In this very limited study, we showed that SRR in vascularly active advanced pediatric vasoproliferative disorders with total retinal detachments is effective and promising, although more extensive controlled trials will be needed to confirm its safety and efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219(4587):983–985

    Article  CAS  Google Scholar 

  2. Lin KL, Hirose T, Kroll AJ, Lou PL, Ryan EA (2009) Prospects for treatment of pediatric vitreoretinal diseases with vascular endothelial growth factor inhibition. Semin Ophthalmol 24(2):70–76

    Article  Google Scholar 

  3. Bates DO, Harper SJ (2002) Regulation of vascular permeability by vascular endothelial growth factors. Vasc Pharmacol 39(4–5):225–237

    Article  CAS  Google Scholar 

  4. Sonmez K, Drenser KA, Jr CA, Trese MT (2008) Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 115(6):1065–1070

    Article  Google Scholar 

  5. Stewart MW (2012) Bevacizumab for retinopathy of prematurity. Ophthalmology 119(5):1091

    Article  Google Scholar 

  6. Xu Y, Zhang Q, Kang X, Zhu Y, Li J, Chen Y, Zhao P (2013) Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection. Acta Ophthalmol 91(4):e304–e310

    Article  CAS  Google Scholar 

  7. Wallace DK (2016) Anti-VEGF treatment for ROP: which drug and what dose? J AAPOS 20(6):476–478

  8. Huang Q, Zhang Q, Fei P, Xu Y, Lyu J, Ji X, Peng J, Li YA, Zhao P (2017) Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology 124(8):1156–1164

    Article  Google Scholar 

  9. Wu AL, Wu WC (2018) Anti-VEGF for ROP and pediatric retinal diseases. Asia Pac J Ophthalmol (Phila) 7(3):145–151

  10. Peng J, Zhang Q, Jin H, Fei P, Zhao P (2017) A modified technique for the transconjunctival and sutureless external drainage of subretinal fluid in bullous exudative retinal detachment using a 24-G i.v. catheter. Ophthalmologica 238(4):6

    Article  Google Scholar 

  11. Ghorbanian S, Jaulim A, Chatziralli IP (2012) Diagnosis and treatment of coats’ disease: a review of the literature. Ophthalmologica 227(4):175

    Article  CAS  Google Scholar 

  12. Jia RB, Zhang P, Zhou YX, Song X, Liu HY, Wang LZ, Luo M, Lu J, Ge SF, Fan XQ (2007) VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res 39(2):108–115

    Article  CAS  Google Scholar 

  13. Lee SY, Kim DK, Cho JH, Koh JY, Yoon YH (2008) Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol 126(7):953–958

    Article  CAS  Google Scholar 

  14. Ho M, Yip WW, Chan VC, Yong AL (2017) Successful treatment of refractory proliferative retinopathy of incontinentia pigmenti by intravitreal ranibizumab as adjunct therapy in a 4-year-old child. Retin Cases Brief Rep 11(4):352

    PubMed  Google Scholar 

  15. Ni Y, Huang X, Ruan L, Xue K, Yu J, Peng J, Zhao P (2018) Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti. J AAPOS 22(4):325–327.e3

    Article  Google Scholar 

  16. Sun Y (2016) Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term. BMC Ophthalmol 16(1):150

    Article  Google Scholar 

  17. Hoerster R, Muether P, Dahlke C, Mehler K, Oberthuer A, Kirchhof B, Fauser S (2013) Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol 91(1):e74–e75

    Article  CAS  Google Scholar 

  18. Zhou Y, Jiang Y, Bai Y, Wen J, Chen L (2016) Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol 254(1):1–6

    Article  Google Scholar 

  19. Bakri S, Snyder M, Reid J, Pulido J, Ezzat M, Singh R (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114(12):2179–2182

    Article  Google Scholar 

  20. Wu WC, Shih CP, Lien R, Wang NK, Chen YP, Chao A, Chen KJ, Ys H, Lai CC (2017) Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina 37(4):694–701

    Article  Google Scholar 

  21. Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, Wu WC (2016) Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS One 11(1):e0148019

    Article  Google Scholar 

  22. Pertl L, Steinwender G, Mayer C, Hausberger S, Pöschl EM, Wackernagel W, Wedrich A, El-Shabrawi Y (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One 10(6):e0129383

    Article  Google Scholar 

Download references

Acknowledgments

This study was partially supported by Science and Technology Commission of Shanghai Municipality (No.17411952900) and the National Natural Science Foundation of China (Grant No. 81770964 and No. 81470642). The sponsor or funding organization had no role in the design or conduct of this research.

Funding

This study was funded by Science and Technology Commission of Shanghai Municipality (17411952900) and the National Natural Science Foundation of China (Grant No. 81470642 and No. 81770964).

Author information

Author notes

  1. Jie Peng and Tingyi Liang contributed equally to this work.

Authors and Affiliations

  1. Department of ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Jie Peng, Tingyi Liang, Qi Zhang, Yu Xu, Jingjing Liu & Peiquan Zhao

  2. Department of ophthalmology, Tianjin Medical University Eye Hospital & Tianjin Medical University Eye Institute, Tianjin, China

    Chunli Chen

  3. Department of ophthalmology, Shengli Oilfield Central Hospital, Shan dong Province, China

    Chunli Chen

Authors
  1. Jie Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tingyi Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chunli Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jingjing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peiquan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peiquan Zhao.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peng, J., Liang, T., Chen, C. et al. Subretinal injection of ranibizumab in advanced pediatric vasoproliferative disorders with total retinal detachments. Graefes Arch Clin Exp Ophthalmol 258, 1005–1012 (2020). https://doi.org/10.1007/s00417-020-04600-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-020-04600-3

Keywords

Search

Navigation